Updated EPS estimates from stock analysts for April 21 (ADMA, AFLYY, AIKI, ASX, ATIP, AUGX, AVA, AVDX, BAM, BBAI)

0

Updated EPS estimates from equity analysts for Thursday, April 21:

ADMA Biologics (NASDAQ: ADMA) was downgraded by analysts from Zacks Investment Research from a hold price to a sell price. According to Zacks, “ADMA Biologics, Inc. is an immunoglobulin company. It develops, manufactures and intends to market plasma-based biological products for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immunocompromised individuals who have an underlying immunodeficiency disease or who may be immunocompromised for medical reasons. Its lead product candidate, RI-002, which is in a phase III clinical trial, is intended for the treatment of primary immunodeficiency. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey. “

Air France-KLM (OTCMKTS:AFLYY) has been updated by analysts from Zacks Investment Research from a sell note to a hold note. According to Zacks, “AIR FRANCE-KLM is an airline. The principal activity of the Company is passenger transportation, cargo transportation and aircraft maintenance services. The Group is the world leader in terms of international passenger traffic; and its cargo business (excluding integrators) and is one of the world’s leading providers of maintenance services. The structure of the Group is simple: a holding company with two airline subsidiaries. Air France-KLM has implemented a set of clearly defined commitments to ensure that its profitable growth strategy goes hand in hand with environmental quality and social progress. “

AIkido Pharma (NASDAQ:AIKI) has been updated by analysts from Zacks Investment Research from a sell note to a hold note. According to Zacks, “AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early-stage small molecule cancer therapies. The Company’s therapeutics pipeline includes therapies for pancreatic cancer, acute myeloid leukemia and acute lymphoblastic leukemia. AIkido Pharma Inc., formerly known as Spherix Incorporated, is based in New York. ”

ASE Technology (NYSE:ASX) was downgraded by analysts from Zacks Investment Research from a hold price to a sell price. According to Zacks, “ASE Technology Holding Co Ltd. is a provider of semiconductor manufacturing services in the areas of assembly and testing. The company develops and offers complete turnkey solutions covering front-end engineering testing, wafer probing and final testing as well as integrated circuit packaging, materials and electronic manufacturing services. It mainly operates in Taiwan, China, South Korea, Japan, Singapore, Malaysia, Mexico, the United States and Europe. ASE Technology Holding Co Ltd, formerly known as ASE Industrial Holding Co., is based in Kaohsiung, Taiwan. “

ATI Physiotherapy (NYSE: ATIP) was downgraded by analysts from Zacks Investment Research from a hold price to a sell price. According to Zacks, “ATI Physical Therapy Inc. is a portfolio company of Advent International as well as a provider of outpatient physical therapy services. ATI Physical Therapy Inc., formerly known as Fortress Value Acquisition Corp. II, is based in NEW YORK. “

Augmedix (OTCMKTS:AUGX) has been updated by analysts at Zacks Investment Research from a sell note to a hold note. According to Zacks, “Augmedix Inc. is a provider of remote medical documentation and live clinical support. Augmedix Inc. is based in SAN FRANCISCO, California.”

Avista (NYSE: AVA) has been updated by analysts from Zacks Investment Research from a sell note to a hold note. According to Zacks, “Avista Corporation is an energy company involved in power generation, transmission, distribution and other energy-related activities. Avista Utilities is its operating division that provides electrical service customers and natural gas customers.Its service territory covers eastern Washington, northern Idaho and parts of southern and eastern Oregon.Alaska Energy and Resources Company is a subsidiary of Avista which provides retail electric service in the city and borough of Juneau, Alaska through its subsidiary Alaska Electric Light and Power Company.”

AvidXchange (NASDAQ: AVDX) has been updated by analysts from Zacks Investment Research from a sell note to a hold note. According to Zacks, “AvidXchange Holdings Inc. is a provider of accounts payable automation software and payment solutions for mid-market enterprises and vendors. The company’s software-as-a-service-based end-to-end payments and software platform digitizes and automates AP workflows for businesses and vendors. AvidXchange Holdings Inc. is based in CHARLOTTE, NC”

Brookfield Asset Management (NYSE: BAM) (TSE: BAM.A) has been updated by analysts from Zacks Investment Research from a sell note to a hold note. According to Zacks, “Brookfield Asset Management Inc. is an asset manager. Focused on real estate, energy and infrastructure assets, the company has assets under management and is co-listed on the New York and Toronto stock exchanges under the symbol BAM. At Brookfield, they continually strive to ensure they have sound corporate governance practices to maintain investor confidence in the way they do business. To ensure it communicates its practices and commitment to strong corporate governance, they are proud to share with its Corporate Governance Statement, Corporate Disclosure Policy, Code of Conduct and ethics and other related information about its corporate governance initiatives and practices. “

BigBear.ai (NYSE: BBAI) has been updated by analysts from Zacks Investment Research from a sell note to a hold note. According to Zacks, “BigBear.ai is a provider of cloud-based artificial intelligence, machine learning, big data analytics, and cyber engineering solutions. BigBear.ai, formerly known as GigCapital4 Inc., is based in COLUMBIA, Md.”

Boston Properties (NYSE: BXP) was raised by analysts at Mizuho from a neutral rating to a buy rating.

KnowBe4 (NASDAQ: KNBE) has had its Buy rating reaffirmed by analysts at Cowen Inc. They currently have a price target of $35.00 on the stock.

Milestone Pharmaceuticals (NASDAQ: MIST) was raised by Piper Sandler analysts from a neutral rating to an overweight rating.



Receive daily news and reviews for ADMA Biologics Inc. – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for ADMA Biologics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.


Source link

Share.

About Author

Comments are closed.